Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Click to visit the #AdvantageHers resource hub to read @CaroWoznaicki top tips for creating a chronic inflammatory disease game plan: https://t.co/kKwruXQRXx https://t.co/HbjffY5ujC
— UCB News (@ucb_news) 04.03.2021 -
Better, faster and more consistent #trialdesignoutcomes will give our colleagues more time to focus on value-added impact. Find out more about #UCBs pioneering End to End Clinical Study Automation program here https://t.co/Agg0FcWxFE
— UCB News (@ucb_news) 04.03.2021 -
UCB augments its scientific standing in the targeting of protein-protein interactions with small molecules through back-to-back new publications in Nature Communications. You can read the publications here (https://t.co/FhPYdqEjal) and here (https://t.co/
— UCB News (@ucb_news) 03.03.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
